Stereoselective effects of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies

Neuropharmacology

Volumn 35, Issue 12, 1996, Pages 1681-1688

  Lodge, David ^a   Bond, Ann ^a   O'Neill, Michael J ^a   Hicks, Caroline A ^a   Jones, Martyn G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

2,3 benzodiazepines; AMPA receptor; global ischaemia; kainate; N methyl D aspartate (NMDA); spinal neurones

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BENZODIAZEPINE DERIVATIVE; GLUTAMATE RECEPTOR ANTAGONIST; KAINIC ACID; LY 303071; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; ENANTIOMER; FEMALE; GERBIL; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BENZODIAZEPINES; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; ISCHEMIC ATTACK, TRANSIENT; ISOMERISM; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; SPINAL CORD; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 0030483662     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00155-4     Document Type: Article

References (39)

1. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaetthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79:1983;565-575.
2. Arvin B., Moncada C., Le Peillet E., Chapman A., Meldrum B.S. GYKI 52466 blocks the increase in extracellular glutamate induced by ischaemia. Neuroreport. 3:1992;235-238.
3. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., Woolley M.L., Bufton H.R., Kamboj R.K., Tarnawa I., Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35:1997;1689-1702.
4. Buchan A.M., Li H., Cho S., Pulsinelli W.A. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adults rats. Neurosci. Lett. 132:1991;255-258.
5. Bullock R., Graham D.I., Swanson S., McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY293558 in focal ischemia in the cat. J. Cereb. Blood Flow Metab. 14:1994;466-471.
6. Chapman A.G., Smith S.E., Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466. Epilepsy Res. 9:1991;92-96.
7. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drugs News Perspect. 8:1995;261-277.
8. Diemer N.H., Jorgensen M.B., Johansen F.F., Sheardown M., Honore T. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta Neurol. Scand. 86:1992;45-49.
9. Dingledine R., McBain C.J., McNamara J.O. Excitatory amino acids in epilepsy. Trends Pharmacol. Sci. 11:1990;334-338.
10. Donevan S.D., Rogawski M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 10:1993;51-59.
11. Donevan S.D., Yamaguchi S.-I., Rogawski M.A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther. 271:1994;25-29.
12. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cereb. Brain Metab Rev. 6:1994;225-256.
13. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischaemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7:1987;3343-3349.
14. Gill R., Foster A.C., Woodruff G.N. MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period. Neuroscience. 25:1988;847-855.
15. Gill R., Lodge D. The neuroprotective effects of the decahydroisoquinoline, LY293558; a novel AMPA antagonist in focal ischemia. Neuropharmacology. 33:1995;1529-1536.
16. Gill R., Nordholm L., Lodge D. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in a rat focal ischemia model. Brain Res. 580:1992;35-43.
17. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J. Pharmacol. Exp. Ther. 276:1996;1-4.
18. Jones M.G., Bond A., Lodge D. Antagonism of excitatory amino acid evoked responses of rat spinal neurones in vivo by 2,3-benzodiazepines GYKI 52466 and 53655. Br. J. Pharmacol. 107:1992;243P.
19. Judge M.E., Sheardown M.J., Jacobsen P., Honore T. Protection against post-ischemic behavioral pathology by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil. Neurosci. Lett. 133:1991;291-294.
20. Le Peillet E., Arvin B., Moncada C., Meldrum B.S. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient ischaemia in the rat. Brain Res. 571:1992;115-120.
21. Li H., Buchan A.M. Treatment with an AMPA antagonist 12 hours following normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. 13:1993;933-939.
22. Lodge D., Bond A., Palmer A.J. Stereospecific effects of 2,3-benzodiazepines as antagonists of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA). Br. J. Pharmacol. 112:1994;13P.
23. Lodge D., Jones M.G., Palmer A.J. Excitatory amino acids: new tools for old stories. Can. J. Physiol. Pharmacol. 69:1991;1123-1128.
24. Lodge D., Jones M.G., Palmer A.J. and Zeman S. (1992) Electrophysiology of glutamate receptors. In: Drug Research Related to Neuroactive Amino Acids (Schousboe A., Diemer N.H. and Kofod H., Eds), pp. 153-160. Munksgaard, Copenhagen.
25. Loscher W., Honack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparisons with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113:1994;1349-1357.
26. Meldrum B.S., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11:1990;379-383.
27. Ouardouz M., Durand J. GYKI 52466 antagonizes glutamate responses but not NMDA and kainate responses in rat abducens motoneurons. Neurosci. Lett. 125:1991;5-8.
28. Pulsinelli W.A., Cho S. Blockade of the AMPA receptor beginning 8 hours after transient ischaemia attenuates CA1 hippocampal injury in rats. Neurology. 3((Suppl.)):1992;532S.
29. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
30. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honoré T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
31. Sheardown M.J., Suzdak P.D., Nordholm L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil ischaemia. Eur. J. Pharmacol. 236:1993;347-353.
32. Smith S.E., Meldrum B.S. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke. 23:1992;861-864.
33. Smith S.E., Durmuller N., Meldrum B.S. The non-N-methyl-D-aspartate antagonists, GYKI 52466 and NBQX, are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:1991;179-183.
34. Tarnawa I., Farkas S., Bersenyi P., Pataki A., Andrasi F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 167:1990;193-199.
35. Vizi E.S., Mike A., Tarnawa I. 2,3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Rev. 2:1996;91-126.
36. Watkins J.C., Krogsgaard-Larsen P., Honoré T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 11:1990;25-33.
37. Xue D., Huang Z.G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. 14:1994;251-261.
38. Yamaguchi S., Donevan S.D., Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:1993;179-184.
39. Zorumski C.F., Yamada K., Price M.T., Olney J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. 10:1993;61-67.